Abel Hall LLC’s Altimmune ALT Stock Holding History

Abel Hall LLC’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-11,527	Closed	-$35K	–	902
2026 Q2	$35K	Buy	+11,527	New	+$34.4K	0.01%	916

Other funds holding ALT

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Beirne Wealth Consulting Services Shelton, Connecticut $505M AUM 16.24% 1-Year Est. Return

BWM

Brown Wealth Management Naperville, Illinois $456M AUM 10.79% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $370M AUM 63.53% 1-Year Est. Return

Summit Financial Wealth Advisors Lafayette, Louisiana $807M AUM 19.93% 1-Year Est. Return

Leonteq Securities AG Zurich, Switzerland $2.44B AUM 50.17% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Abel Hall LLC's ALT Position: Q3 2026 in Review

Abel Hall LLC sold out of Altimmune (ALT) in Q3 2026, closing a stake of 11,527 shares — an estimated $35K sold.

Abel Hall LLC first reported a position in ALT in Q2 2026 and held it in 1 quarter. The position peaked at $35K in Q2 2026. 38 funds tracked by Wall St. Rank hold ALT as of Q3 2026.

Abel Hall LLC reported no remaining Altimmune position as of Q3 2026 after selling out during the quarter.
Abel Hall LLC sold 11,527 Altimmune shares in Q3 2026, an estimated $35K.
Abel Hall LLC first reported a position in Altimmune in Q2 2026 and held it in 1 quarter.
Abel Hall LLC's Altimmune position peaked at $35K in Q2 2026.
38 funds tracked by Wall St. Rank held Altimmune as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.